Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
Clinical trial NCT03910452 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03910452
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-28
- Primary completion
- 2034-06-15
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.